EDC for trials under 100 patients: Phase 1–2 scale, 21 CFR Part 11–aligned controls, and one platform without enterprise overhead.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
Under-100-patient trials span a wide range of designs, each with specific EDC requirements. Phase 1 dose-escalation studies with 3+3 cohort designs need flexible visit structures and the ability to add new dose cohorts as safety data accumulates. Randomized Phase 1b studies may require multi-arm support with different CRF configurations per arm. Proof-of-concept studies need efficacy endpoint capture alongside safety monitoring. And pilot or feasibility studies may test operational assumptions like enrollment rates, ePRO completion, and site performance. Capture supports all of these designs within a single platform. Study builders configure the visit schedule, CRF structure, randomization scheme, and conditional logic through the browser. When the protocol requires mid-study changes—adding a dose level, modifying a visit window, or updating an inclusion criterion—these amendments are made through the same configuration interface with full audit trail documentation. This flexibility is essential for under-100-patient studies, where protocol evolution based on emerging data is the norm rather than the exception.
When your study has fewer than 100 participants, the value of each data point is magnified. Statistical power is limited, so data completeness and accuracy directly affect the reliability of your conclusions. Missing a single primary endpoint assessment or having unresolved queries at database lock can weaken your analysis and raise questions from sponsors, partners, or regulators reviewing your data package. Capture helps maximize data value through multiple mechanisms. Edit checks at the point of entry catch out-of-range values, missing required fields, and logical inconsistencies before data is saved. Visit scheduling with window tolerances helps coordinators stay on protocol for assessment timing. Query workflows enable rapid identification and resolution of data issues. And because all data—consent, CRFs, ePRO, and safety—is captured in one system, there are no reconciliation gaps that might leave data quality issues undetected until database lock. For studies where every participant matters, this built-in data quality infrastructure is not optional—it is essential for producing results that can withstand scrutiny and support program advancement decisions.
Under-100-patient studies are often stepping stones to larger programs. A successful Phase 1b may lead to a multi-site Phase 2. A positive POC result may trigger expansion into a registrational study. When these transitions happen, teams that built their earlier study on Capture can carry their data infrastructure forward. CRF designs, consent templates, visit structures, and export formats developed for the under-100-patient study can be cloned and adapted for the next protocol. Sites already trained on Capture can be retained for the larger study with minimal re-onboarding. Statistical programming pipelines built against Capture export structures require only incremental updates. And validation documentation from the earlier study can be referenced and extended for the new program, reducing the time and cost of system qualification. This continuity across study phases is particularly valuable for small biotech and startup sponsors who need to demonstrate program momentum to investors and partners. Being able to transition from a successful under-100-patient study to a larger program without changing EDC platforms sends a signal of operational maturity and reduces the risk associated with technology transitions.
Overview
Trials with under 100 patients—Phase 1, 1a, 1b, pilot, proof-of-concept, or early Phase 2—represent the majority of clinical studies in early drug development. These studies generate the safety, pharmacokinetic, and early efficacy data that determine whether a program advances to larger confirmatory trials. Despite their smaller cohort sizes, the data quality requirements are rigorous: sponsors, regulatory authorities, and ethics committees expect the same level of auditability, data integrity, and participant privacy protection as larger programs. The challenge for teams running under-100-patient trials is finding an EDC system that balances compliance requirements with practical constraints. Enterprise EDC platforms designed for multi-thousand-patient Phase 3 programs come with pricing, implementation timelines, and feature complexity that create friction for smaller studies. At the same time, under-100-patient trials are not simple: they may involve dose escalation cohorts, randomization, multiple treatment arms, biomarker-driven enrollment, hybrid visit models, and both clinician-assessed and patient-reported endpoints. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. The platform supports the full range of under-100-patient study designs—from straightforward single-arm safety studies to complex adaptive POC trials—with a setup and operational footprint that matches the team size. Study builders configure forms, visits, randomization, and edit checks through the browser. Coordinators capture data through a clean web interface. And data managers export structured datasets ready for analysis. Because Capture integrates consent, CRF data, ePRO, and safety in one system, teams avoid the operational overhead and compliance risks that come with patching together multiple tools for a study that will ultimately produce a unified dataset for analysis and regulatory review.
Trials under 100 patients require audit trails, access controls, and data integrity for regulatory and sponsor review. The data from these studies often drives critical investment decisions: a 30-patient Phase 1b study may determine whether a sponsor commits to a $50M Phase 2 program. A 60-patient POC trial may be the basis for a partner licensing discussion. Data quality at this stage has outsized impact on the program trajectory. Enterprise EDC platforms often target large Phase 3 programs with pricing models based on per-site fees, per-patient fees, or module bundling that creates cost-to-value misalignment for under-100-patient studies. Implementation timelines that assume a large project team and multi-month rollout do not fit the pace of early-phase development, where speed to first patient is often measured in weeks. Capture is built for early-phase and mid-size trials: one platform, one audit trail, and controls aligned with 21 CFR Part 11 without enterprise overhead. The pricing and deployment model is designed for under-100-patient studies specifically, so teams get the compliance infrastructure they need without paying for capabilities designed for global registrational programs.
FAQ
Explore the platform with a free sandbox. No sales call required.